Butadion, tablets 150 mg 20 pcs

Pharmgroup:

NSAIDs.

Pharm Action:

PNP, has anti-inflammatory, analgesic and antipyretic effects associated with inhibition of COX activity, and COX2, regulating the synthesis of PG. Exhibits uricosuric action.

Pharmacokinetics:

In oral administration absorption – high; bioavailability – 85-90%, reduced with prolonged administration. TCmax – 1-2 hours. Binding to plasma proteins – more than 95%.

It is metabolized in the liver with the formation of 2 main metabolites. T1/2 – 18-24 hours. It is excreted by the kidneys 70% (5% unchanged), through the gastrointestinal tract – 30% as metabolites, a significant amount is excreted with the breast milk.

Indications

Small area I and II degree burns, including sunburns; Dermatitis, skin inflammations at the site of intramuscular or intravenous injections, insect bites; inflammation of hemorrhoidal nodes and superficial thrombophlebitis; traumatic soft tissue injuries; Bechterew’s disease, erythema nodosa, minor chorea, etc.

Butadion is used for treatment of joint diseases of different etiology – acute and subacute stages of articular rheumatism (however inferior to salicylates in heart disease complicated by endomyocarditis and circulatory disorders), acute, subacute and chronic rheumatoid polyarthritis, non-specific infectious polyarthritis, gout, thrombophlebitis, osteoarthritis, tendinitis, tendovaginitis.

The beneficial effect of Butadion is noted in bronchial asthma, neuralgia, neuritis, myalgia.

Active ingredient

Composition

Phenylbutazone 150 mg.

How to take, the dosage

Overly, 0.2-0.4 g during or after meals 3-4 times a day.

In children aged from 6 months – 0.01-0.1 g (depending on age) 3-4 times a day. Duration of therapy – 2-5 weeks or more.

Interaction

Enhances the effect of indirect anticoagulants, antiaggregants, fibrinolytics, side effects of GCS and MKS, estrogen, morphine, PASC, penicillin, hypoglycemic effect of sulfonylurea derivatives.

Decreases the effectiveness of uricosuric, hypotensive drugs and diuretics.

Increases the blood concentration of Li+ drugs, methotrexate.

Inducers of microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, tricyclic antidepressants) increase the production of hydroxylated active metabolites.

Antacids and colestyramine decrease absorption.

Myelotoxic drugs increase the manifestations of hematotoxicity of the drug.

Special Instructions

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study.

At the time of treatment the patient should refrain from potentially hazardous activities requiring increased attention and rapid mental and motor reactions. To decrease the risk of gastrointestinal adverse events, the lowest effective dose should be used for the shortest possible course.

Contraindications

Hypersensitivity; complete or incomplete combination of bronchial asthma, recurrent nasal and paranasal sinus polyposis and intolerance to ASA or other. NSAIDs (incl.
gastrointestinal erosive and ulcerative lesions in aggravation stage (gastric and duodenal ulcer, ulcerative colitis, peptic ulcer), bone marrow depression, decompensated CHF or pulmonary and cardiac insufficiency, severe hepatic and/or renal insufficiency (CKG

Side effects

Digestive system disorders: dyspepsia, NSAID gastropathy, abdominal pain, nausea, vomiting, heartburn, diarrhea or constipation; with long-term use in high doses – ulceration of the gastrointestinal mucosa, aphthous stomatitis, glossitis, erosive esophagitis, bleeding (gastrointestinal, gingival, hemorrhoidal), liver function failure.

Systemic system disorders: increase in blood pressure and tachycardia.

Nervous system disorders: headache, dizziness, drowsiness, depression, agitation.

Sensory system disorders: decreased hearing, tinnitus.

Hematopoietic organs: agranulocytosis, leukopenia, anemia, thrombocytopenia.

Allergic reactions: skin rash, itching, urticaria, bronchospasm, edema syndrome, angioedema.

Others: increased sweating, uterine bleeding.

Overdose

Symptoms: cyanosis of fingertips, lips, body skin, dizziness, headache, high or low blood pressure, hyperventilation of the lungs, blurred consciousness, in children – myoclonic convulsions, nausea, vomiting, abdominal pain, hemorrhages, liver and kidney malfunction.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy to maintain vital body functions. Forced diuresis and hemodialysis are ineffective.